Ronald Eric Long

Biacore International AB offers systems that generate data on the interactions between proteins and small molecule drug candidates. Its systems are used in pharmaceutical drug discovery, antibody characterization, proteomics, immunogenicity, biotherapeutic development and manufacture and life science research applications. The company serves research centers, pharmaceutical and biotechnology companies. Biacore International markets its products in the United States, Europe, Japan and Australia. The company was founded in 1984 and is headquartered in Uppsala, Sweden

Gyros AB engages in the utilization of microfluidic technologies to miniaturize and automate immunoassays. Its Gyrolab xP miniaturizes, integrates, and automates analysis of samples in parallel. The firm's technology delivers immunoassay data through automated control of centrifugal and capillary forces to steer liquid flow in proprietary nanoliter-scale microfluidic structures.The company offers Gyrolab microlaboratory, in the form of a compact disk, can process samples at nanoliter scale, controlled by Gyrolab Workstation. Gyros was founded in 2000 and is headquartered in Uppsala, Sweden.

Biomonitor ApS conducts research and development focusing on developing bioassays to monitor patients’ response to biological therapeutics. It offers services in the field of biopharmaceuticals, patient monitoring services through measurement of drug levels and immunogenicity of biopharmaceuticals in patients under therapy of these drugs, and customized reporter-gene cell-based assay development. The company was founded by Klaus Bendtzen and Arsalan Kharazmi on October 30, 2003 and is headquartered in Herlev, Denmark.

Procognia Ltd. provides technology for the development of glycoprotein drugs. It uses protein arrays to understand the function of proteins and their post-translational modifications. Utilizing technologies based around proteins arrays, they provide both the means for disease mechanisms and the discovery and development of drugs to treat those diseases. Procognia uses protein arrays to understand the function of proteins and their post-translational modifications, particularly glycosylation

KuDOS Pharmaceuticals Ltd. discovers and develops pharmaceutical products. Its products are used to treat DNA damage sensing, signaling, viral disease, ischaemia, and repair to address unmet medical needs in cancer treatment. The company was founded by Stephen Jackson on December 12, 1997 and is headquartered in Cambridge, UK.